Page last updated: 2024-10-30

lorazepam and Drug Refractory Epilepsy

lorazepam has been researched along with Drug Refractory Epilepsy in 2 studies

Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.

Research Excerpts

ExcerptRelevanceReference
" Five patients were sedated with initial lorazepam dose, but this side effect resolved on dosage reduction."1.72Enteral lorazepam is a promising weaning strategy for midazolam-responsive febrile infection-related epilepsy syndrome (FIRES): a case series ( Chaitra, R; Jain, V; Konanki, R; Sharma, R; Srivastava, K, 2022)
" Our objective was to evaluate BZD dosing in SE patients and its effects on clinical/electrographic outcomes."1.48Inadequate benzodiazepine dosing may result in progression to refractory and non-convulsive status epilepticus. ( Ibrahim, M; Mahulikar, A; Mohamed, W; Rao, SK; Seraji-Bozorgzad, N; Shah, A, 2018)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Jain, V1
Konanki, R1
Chaitra, R1
Srivastava, K1
Sharma, R1
Rao, SK1
Mahulikar, A1
Ibrahim, M1
Shah, A1
Seraji-Bozorgzad, N1
Mohamed, W1

Other Studies

2 other studies available for lorazepam and Drug Refractory Epilepsy

ArticleYear
Enteral lorazepam is a promising weaning strategy for midazolam-responsive febrile infection-related epilepsy syndrome (FIRES): a case series
    Epileptic disorders : international epilepsy journal with videotape, 2022, 08-01, Volume: 24, Issue:4

    Topics: Child; Drug Resistant Epilepsy; Encephalitis; Epileptic Syndromes; Humans; Lorazepam; Male; Midazola

2022
Inadequate benzodiazepine dosing may result in progression to refractory and non-convulsive status epilepticus.
    Epileptic disorders : international epilepsy journal with videotape, 2018, Aug-01, Volume: 20, Issue:4

    Topics: Adult; Aged; Anticonvulsants; Benzodiazepines; Coma; Disease Progression; Drug Resistant Epilepsy; F

2018